Content uploaded by Thomas Franke
Author content
All content in this area was uploaded by Thomas Franke on Apr 21, 2021
Content may be subject to copyright.
A preview of the PDF is not available
20210408 Endbericht s4pt 2
Abstract
The research project "Security for Pharma Transportation" (s4pt) aimed to make the supply chains for pharmaceutical products, which require special protection, as secure as possible. Within the funding period, software was developed that uses predictive algorithms to assess and avoid risks from the production of precursors through the entire manufacturing and logistics process to delivery. In order to take into account the requirements of globally networked commodity chains, weather phenomena, political influences affecting trade and criminal threat scenarios were included as a database in addition to production variables. Legal issues were taken into account from the outset and the feasibility of the solutions in the project was ensured. Project partners were: Forum Vernetzte Sicherheit gGmbH, Center for European and International Criminal Law Studies (University of Osnabrück), netwiss OG, MANOVA GmbH, RUSSIA Fachspedition Dr. Lassmann GmbH, Upper Austria University of Applied Sciences, Steyr, and the Federal Transport and Traffic Division in the Austrian Federal Economic Chamber. The project was financially supported by the Federal Ministry of Education and Research within the framework of the directive "Research for Civil Security, Announcement: "Civil Security - Critical Structures and Processes in Production and Logistics" and the Österreichische Forschungsförderungsgesellschaft mbH for the period from March 2019 to February 2021. This report shows the findings of the research.
ResearchGate has not been able to resolve any citations for this publication.
• Understanding uncertainty in the COVID-19 pandemic is a priority for the industry. • Policy and population behavioral affect risk management in the short/mid-term. • Information around natural history unknowns will guide long-term risk management. • Our framework allows risk management and risk-sharing strategies discussions.
The coronavirus pandemic (COVID-19) is currently putting high pressure on most countries' critical infrastructures (not only health care), creating huge uncertainties in supply and demand, and disrupting global supply chains. The global crisis will demonstrate the extent to which different parties (countries, public authorities, private companies etc.) can work together and take holistic decisions in such situations. A core question in supply chain management asks how independent decision-makers at many levels can work together and how this joint work can be governed. Supply chain risk management (SCRM), however, has focused mostly on how focal private companies apply SCRM processes to identify, analyse and mitigate risk related to upstream and downstream flows in their supply networks. At the same time, inter-organisational collaboration to handle diverse risks is always needed. A risk that hits one organisation often affects other, interconnected organisations. This study aims to develop the term supply chain risk governance with an associated conceptual framework that embraces various types of supply chains and actors. In a cross-disciplinary literature study, we dissect, compare and combine risk governance with inter-organisational aspects of SCRM and find that the mechanisms suggested in the risk governance literature coincide with many of those in SCRM. We suggest a combination of these to govern risk processes at an inter-organisational level, regardless of the type of organisation included in the supply chain. This would be suitable for critical infrastructures that often contain a mixture of private and public actors. The scope of the literature employed is limited, and some articles have played a larger role in the framework development. The paper explores new territory through this cross-disciplinary study, extends existing multi-level frameworks with inter-organisational governance mechanisms and proposes new governance mechanisms to the field. This study could support the understanding of how critical infrastructures in our society are governed so as to increase their resilience to both smaller and larger disruptions.
Purpose
The purpose of the study is to determine and prioritize the resilient capability factors at different stages of supply chain disruptions in Pakistan's textile industry.
Design/methodology/approach
The study employs a two-stage methodology. In the first stage, the extant literature was reviewed, and based on that, experts' panel consultations were conducted to identify the resilient capability factors at the different stages of supply chain. In the second stage, analytical hierarchy process (AHP) methodology was used to rank the resilient capability factors needed in Pakistan's textile industry.
Findings
The results show that building an integrated supply chain ranking is one of the most critical practices in bolstering supply chain resilience. The results also reveal that firms should focus on the readiness phase of resilience as it is categorized as the most important phase.
Practical implications
The findings of the study provide supply chain professionals with a clear consideration of the critical factors that are needed to build supply chain resilience. From an industry-specific perspective, the study offers guidelines on what resilient capability factors should be regarded as critical when implementing resilient capabilities in order to reduce the negative impacts of disruptions.
Originality/value
The study is among the first studies in prioritizing the resilient capability factors at different phases of supply chain disruptions. The study would provide further opportunities for future researchers in using other multicriteria decision-making tools.
The top priority of today’s healthcare system is delivering medicine directly from the manufacturer to end-user. The pharmaceutical supply chain involves some level of commingling of a collection of stakeholders such as distributors, manufacturers, wholesalers, and customers. The biggest challenge associated with this supply chain is temperature monitoring as well as counterfeit drug prevention. Many drugs and vaccines remain viable within a specific range of temperatures. If exposed beyond this temperature range, the medicine no longer works as intended. In this paper, an Internet of Things (IoT) sensor-based blockchain framework is proposed that tracks and traces drugs as they pass slowly through the entire supply chain. On the one hand, these new technologies of blockchain and IoT sensors play an essential role in supply chain management. On the other hand, they also pose new challenges of security for resource-constrained IoT devices and blockchain scalability issues to handle this IoT sensor-based information. In this paper, our primary focus is on improving classic blockchain systems to make it suitable for IoT based supply chain management, and as a secondary focus, applying these new promising technologies to enable a viable smart healthcare ecosystem through a drug supply chain.
The COVID-19 pandemic has caused a dramatic shortage in medical supplies needed to treat the virus due to a massive surge in demand as the disease circled the globe during the first half of 2020. Prior to the crisis, there was an interdependence of trade and production for medical supplies, with advanced industrial countries like the United States and Germany specializing in the relatively high-tech medical devices sector, while low-cost production hubs such as China and Malaysia were leading producers of less technologically sophisticated personal protective equipment (PPE) products such as face masks, surgical gloves and medical gowns. After the COVID-19 outbreak, global shortages of PPE products emerged as many affected countries imposed export controls and sought ways to boost domestic output. A case study of the face mask value chain in the United States shows misalignments between the priorities of U.S. federal government officials and the strategies of leading U.S. multinational producers of face masks, which resulted in exceptionally costly policy delays in terms of health outcomes. On balance, the U.S. shortage of N95 respirators during the COVID-19 pandemic is more a policy failure than a market failure. The global value chain framework highlights strategic options that could lead to more resilient supply chains and diversified sourcing patterns.
Background
The novel coronavirus disease 2019 (COVID-19) was characterized as a global pandemic by the WHO on March 11th, 2020. This pandemic had major effects on the health market, the pharmaceutical sector, and was associated with considerable impacts; which may appear in short and long-term time-horizon and need identification and appropriate planning to reduce their socio-economic burden.Objectives
Current short communication study assessed pharmaceutical market crisis during the COVID-19 era; discussing short- and long-term impacts of the pandemic on the pharmaceutical sector.ResultsShort-term impacts of COVID-19 pandemic includes demand changes, regulation revisions, research and development process changes and the shift towards tele-communication and tele-medicine. In addition, industry growth slow-down, approval delays, moving towards self-sufficiency in pharm-production supply chain and trend changes in consumption of health-market products along with ethical dilemma could be anticipated as long-term impacts of COVID-19 pandemic on pharmaceutical sector in both global and local levels.Conclusion
The pandemic of COVID-19 poses considerable crisis on the health markets, including the pharmaceutical sector; and identification of these effects, may guide policy-makers towards more evidence-informed planning to overcome accompanying challenges.
.
Research on supply chain resilience (SCRE) capabilities and its performance measurement has been growing in recent years. However, the investigation of these concepts has primarily been conducted independently despite the interdependence of these concepts. A systematic literature review of 153 papers was conducted based on the principles of rigour, transparency and replicability required by the methodology. For the first time, we structurally reviewed the 11 SCRE performance metrics categories and its capabilities in SCRE Capabilities-Performance Metrics Framework (SCPM) developed based on the three resilience dimensions (readiness, response and recovery). The framework enables researchers to seek fundamental knowledge and to pursue further research regarding SCRE assessment. This study also provides practical value offering a guidance for decision-makers considering the trade-off among different capabilities and performance metrics.
Purpose
In the Indian manufacturing SMEs context, supply chains have a complex structure having multiple echelons, multiple partners and multiple locations. Due to these complexities, most of the Indian manufacturing SMEs face several types of supply chain risks. This paper aims to identify the dominant risk variables and to develop the interrelationship among these risk variables.
Design/methodology/approach
Based on the literature review and experts’ opinion, nine dominant risk variables faced by an Indian manufacturing SMEs have been identified. An interpretive structural modelling (ISM) approach has been adopted to establish the interrelationship among the risk variables. These risk variables have been classified by using MICMAC analysis. Based on ISM-MICMAC approach, a case study on three Indian manufacturing SMEs has been carried out.
Findings
This study would help the supply chain managers to understand and prioritize the significant risk variables. Nine significant risks variables of Indian manufacturing small and medium enterprises (SMEs) have been studied. External risk, information technology risk and financial risk have identified as most influencing risk variables, while delay risk and market risk have emerged as the most dependent risk variables. These results will provide a guideline to supply chain managers for implementation of supply chain risk management (SCRM).
Research limitations/implications
In this study, an ISM-based model is developed based on the opinion of experts from a group of Indian manufacturing SMEs; as such, this model may be biased and limited to a selected company. This framework can be extended further by adding more risk variables and sub-risk variables from the other sectors/organizations.
Originality/value
Many SCRM models are available in past literature, but no model has been proposed for the Indian Manufacturing SMEs. This research finding can be useful for managers to understand the characteristics and interrelationships among the risk variables for building a robust supply chain. These results will also help the supply chain managers in making proactive plans for SCRM, especially in the Indian SMEs context.
Purpose
Lean implementation is vastly incorporated in core manufacturing processes; however, its applicability in the supply chain and service industry is still in its infancy. To acquire performance excellence and thrive in the global competitive market, many firms are adopting newer methodologies. But, there is a stringent need for production simulation systems to analyze supply chains both inbound and outbound. The era of face validation is slowly disappearing. Lean tools and procedures that provide future state assumptions need advanced tools and techniques to measure, quantify, analyze and validate them. The purpose of this study is to enable dynamic quantification and visualization of the future state of a warehouse supply chain value stream map using discrete event simulation (DES) technique.
Design/methodology/approach
This study aimed to apply an integrated approach of the value stream mapping (VSM) and DES in a Malaysian pharmaceutical production warehouse. The main focus is diverted towards reducing the warehouse supply chain lead time by initially constructing a supply chain value stream map (both present state and future state) and integrating its data in a DES modelling and simulation software to dynamically visualize the changes in future state value stream map.
Findings
The DES simulation was able to mimic the future state lead time reductions successfully, which assists in better decision-making. Improvements were seen related to total lead time, process time, value and non-value-added percentage. Warehouse performance metrics such as receiving, put away and storage rates were substantially improved along with pallet processing time, worker and forklift throughput usage percentage. Detailed findings are clearly stated at the end of this paper.
Research limitations/implications
This study is limited to the warehouse environment and further additional process models and functional upgrades in the DES software systems are very much needed to directly visualize and quantify all the possible Lean assumptions such as radio frequency image identification/Andon (Jidoka), 5S, Kanban, Just-In-Time and Heijunka. However, DES has a leading edge in extracting dynamic characteristics out of a static VSM timeline and capture details on discrete events precisely by picturizing facility modification and lead time related to it.
Practical implications
This paper includes all the fundamental pharmaceutical warehouse supply chain processes and the simulations of the future state VSM in a real-life context by successfully reducing supply chain lead time and allowing managers in inculcating near-optimal decision-making, controlling and coordinating warehouse supply chain activities as a whole.
Social implications
This integrated approach of DES and VSM can involve managers and top management to support the adoption of anticipated changes. This study also has the potential to engage practitioners, researchers and decision-makers in the warehouse industry.
Originality/value
This study involves a powerful DES software package that can mimic the real situation as a virtual simulation and all the data and model building are based on a real warehouse scenario in the pharmaceutical industry.
The supply of affordable, high-quality pharmaceuticals to US patients has been on a critical path for decades. In and beyond the COVID-19 pandemic, this critical path has become tortuous. To regain reliability, reshoring of the pharmaceutical supply chain to the USA is now a vital national security need. Reshoring the pharmaceutical supply with old know-how and outdated technologies that cause inherent unpredictability and adverse environmental impact will neither provide the security we seek nor will it be competitive and affordable. The challenge at hand is complex akin to redesigning systems, including corporate and public research and development, manufacturing, regulatory, and education ones. The US academic community must be engaged in progressing solutions needed to counter emergencies in the COVID-19 pandemic and in building new methods to reshore the pharmaceutical supply chain beyond the pandemic.